NASDAQ:LONA Athira Pharma Q1 2025 Earnings Report $4.48 +0.10 (+2.28%) As of 10:51 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Athira Pharma EPS ResultsActual EPS-$2.30Consensus EPS -$2.00Beat/MissMissed by -$0.30One Year Ago EPSN/AAthira Pharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAthira Pharma Announcement DetailsQuarterQ1 2025Date5/9/2025TimeBefore Market OpensConference Call DateFriday, May 9, 2025Conference Call Time4:00PM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Athira Pharma Earnings HeadlinesAthira Pharma, Inc. (NASDAQ:LONA) Stock Rated "Moderate Buy" by Wall Street BrokeragesSeptember 29 at 2:44 AM | americanbankingnews.comLeonaBio to Participate in Cantor Global Healthcare Conference 2026September 3, 2026 | globenewswire.comThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO as soon as this fall. TradeSmith CEO Keith Kaplan says chasing the next hot IPO isn't necessary. His AI-driven system, built on a platform pioneered by Google, ranks every stock in the S&P 500 and narrows the list to just five names to hold each month. Backtests show the Top Five Stocks outperformed the S&P 500 by 4x in August alone.October 2 at 1:00 AM | TradeSmith (Ad)Seattle-area biotech led by ex-Athira CEO Leen Kawas raises $35M for hepatitis D drugAugust 31, 2026 | msn.comLeonaBio Reports Second Quarter 2026 Financial Results and Provides Business UpdateAugust 14, 2026 | globenewswire.comLeonaBio to Highlight Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer at DAVA Oncology's 4th Summit on Breast CancerAugust 12, 2026 | globenewswire.comSee More Athira Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Athira Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Athira Pharma and other key companies, straight to your email. Email Address About Athira PharmaAthira Pharma (NASDAQ:LONA) is a biotechnology company focused on developing regenerative medicines for diseases involving neurodegeneration and neurological decline. The company’s research is based on the hepatocyte growth factor (HGF) pathway, which it believes may support neuronal health, repair, and regeneration. Athira’s lead investigational product is fosgonimeton (also known as ATH-1017), a small-molecule therapy designed to activate the HGF/MET system. The treatment has been studied for Alzheimer’s disease and other neurological conditions, although it remains investigational and has not been approved for commercial use. Athira was founded in 2011 and is based in the United States. The company has conducted clinical development activities in the United States and internationally. Public information has identified Leen Kawas as a former chief executive officer; leadership and corporate status may have changed. The ticker provided, NASDAQ:LONA, does not appear to correspond to Athira Pharma, which has historically been associated with the ticker ATHA.View Athira Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Micron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCleared for Takeoff: AAR Corp. Expands Its Aerospace Aftermarket ReachJabil’s Double-Beat and Raise Is a Signal That This Rally Will ContinueMicrosoft's AI Spending Didn't Change—Wall Street's View of It DidL3Harris’ $6 Billion THAAD Win Comes at a Crucial Moment for the Stock Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
